284 related articles for article (PubMed ID: 23283528)
21. Om.breast cancer in very young women aged 25 year-old or below in the center of Tunisia and review of the literature.
Ben Abdelkrim S; Fathallah K; Rouatbi R; Ayachi M; Hmissa S; Mokni M
Pathol Oncol Res; 2015 Jul; 21(3):553-61. PubMed ID: 25962349
[TBL] [Abstract][Full Text] [Related]
22. Primary and secondary distant metastatic breast cancer: two sides of the same coin.
Güth U; Magaton I; Huang DJ; Fisher R; Schötzau A; Vetter M
Breast; 2014 Feb; 23(1):26-32. PubMed ID: 24215983
[TBL] [Abstract][Full Text] [Related]
23. The expression and clinical significance of the androgen receptor and E-cadherin in triple-negative breast cancer.
Tang D; Xu S; Zhang Q; Zhao W
Med Oncol; 2012 Jun; 29(2):526-33. PubMed ID: 21519872
[TBL] [Abstract][Full Text] [Related]
24. Breast carcinomas with isolated bone metastases have different hormone receptor expression profiles than those with metastases to other sites or multiple organs.
Wei S; Li Y; Siegal GP; Hameed O
Ann Diagn Pathol; 2011 Apr; 15(2):79-83. PubMed ID: 21163679
[TBL] [Abstract][Full Text] [Related]
25. Novel prognostic markers for patients with triple-negative breast cancer.
Zhou L; Li K; Luo Y; Tian L; Wang M; Li C; Huang Q
Hum Pathol; 2013 Oct; 44(10):2180-7. PubMed ID: 23845466
[TBL] [Abstract][Full Text] [Related]
26. Male breast cancers behave differently in elderly patients.
Tural D; Selçukbiricik F; Aydoğan F; Beşe N; Yetmen O; Ilvan Ş; Büyükünal E; Serdengeçti S
Jpn J Clin Oncol; 2013 Jan; 43(1):22-7. PubMed ID: 23159765
[TBL] [Abstract][Full Text] [Related]
27. Prognostic factors of early distant recurrence in hormone receptor-positive, postmenopausal breast cancer patients receiving adjuvant tamoxifen therapy: results of a retrospective analysis.
Debled M; MacGrogan G; Brouste V; Mathoulin-Pelissier S; Durand M; Mauriac L
Cancer; 2007 Jun; 109(11):2197-204. PubMed ID: 17450590
[TBL] [Abstract][Full Text] [Related]
28. Age at diagnosis and distant metastasis in breast cancer--a surprising inverse relationship.
Purushotham A; Shamil E; Cariati M; Agbaje O; Muhidin A; Gillett C; Mera A; Sivanadiyan K; Harries M; Sullivan R; Pinder SE; Garmo H; Holmberg L
Eur J Cancer; 2014 Jul; 50(10):1697-1705. PubMed ID: 24768572
[TBL] [Abstract][Full Text] [Related]
29. Differential TAG-72 epitope expression in breast cancer and lymph node metastases: a marker of a more aggressive phenotype.
Galietta A; Pizzi C; Pettinato G; Limite G; Sgambato A; Lamberti M; Muraro R; Formisano C; Pensabene M; Bianco AR; Mariani-Costantini R; Contegiacomo A
Oncol Rep; 2002; 9(1):135-40. PubMed ID: 11748471
[TBL] [Abstract][Full Text] [Related]
30. High expression of OSR1 as a predictive biomarker for poor prognosis and lymph node metastasis in breast cancer.
Li Y; Qin J; Wu J; Dai X; Xu J
Breast Cancer Res Treat; 2020 Jul; 182(1):35-46. PubMed ID: 32424721
[TBL] [Abstract][Full Text] [Related]
31. A Dutch Prediction Tool to Assess the Risk of Additional Axillary Non-Sentinel Lymph Node Involvement in Sentinel Node-Positive Breast Cancer Patients.
van den Hoven I; van Klaveren D; Voogd AC; Vergouwe Y; Tjan-Heijnen V; Roumen RM
Clin Breast Cancer; 2016 Apr; 16(2):123-30. PubMed ID: 26602438
[TBL] [Abstract][Full Text] [Related]
32. Lymph Node Status in Breast Cancer Does Not Predict Tumor Biology.
Bello DM; Russell C; McCullough D; Tierno M; Morrow M
Ann Surg Oncol; 2018 Oct; 25(10):2884-2889. PubMed ID: 29968028
[TBL] [Abstract][Full Text] [Related]
33. Impact of age, tumor size, lymph node metastasis, stage, receptor status and menopausal status on overall survival of breast cancer patients in Pakistan.
Mahmood H; Faheem M; Mahmood S; Sadiq M; Irfan J
Asian Pac J Cancer Prev; 2015; 16(3):1019-24. PubMed ID: 25735323
[TBL] [Abstract][Full Text] [Related]
34. Elevated Interleukin-13 Receptor Alpha 1 Expression in Tumor Cells Is Associated with Poor Prognosis in Patients with Invasive Breast Cancer.
Park MH; Kwon HJ; Kim JR; Lee B; Lee SJ; Bae YK
Ann Surg Oncol; 2017 Nov; 24(12):3780-3787. PubMed ID: 28634667
[TBL] [Abstract][Full Text] [Related]
35. Discordant HER2 status between primary breast carcinoma and recurrent/metastatic tumors using fluorescence in situ hybridization on cytological samples.
Arihiro K; Oda M; Ogawa K; Tominaga K; Kaneko Y; Shimizu T; Matsumoto S; Oda M; Kurita Y; Taira Y
Jpn J Clin Oncol; 2013 Jan; 43(1):55-62. PubMed ID: 23225912
[TBL] [Abstract][Full Text] [Related]
36. Immunohistochemical profile of breast cancer patients at a tertiary care hospital in South India.
Ambroise M; Ghosh M; Mallikarjuna VS; Kurian A
Asian Pac J Cancer Prev; 2011; 12(3):625-9. PubMed ID: 21627355
[TBL] [Abstract][Full Text] [Related]
37. Risk factors and survival outcome in cerebral metastatic breast cancer.
Bachmann C; Schmidt S; Staebler A; Schittenhelm J; Wallwiener D; Grischke EM
Med Oncol; 2014 Mar; 31(3):862. PubMed ID: 24504842
[TBL] [Abstract][Full Text] [Related]
38. Patients with HER2-positive early breast cancer receiving adjuvant trastuzumab: clinicopathological features, efficacy, and factors affecting survival.
Ulas A; Kos T; Avci N; Cubukcu E; Olmez OF; Bulut N; Degirmenci M
Asian Pac J Cancer Prev; 2015; 16(4):1643-9. PubMed ID: 25743846
[TBL] [Abstract][Full Text] [Related]
39. Ki67 expression in breast cancer. Correlation with prognostic markers and clinicopathological parameters in Saudi patients.
Elkablawy MA; Albasri AM; Mohammed RA; Hussainy AS; Nouh MM; Alhujaily AS
Saudi Med J; 2016 Feb; 37(2):137-41. PubMed ID: 26837394
[TBL] [Abstract][Full Text] [Related]
40. Discordant expression of hormone receptors and HER2 in breast cancer. A retrospective comparison of primary tumors with paired metachronous recurrences or metastases.
Arapantoni-Dadioti P; Valavanis C; Gavressea T; Tzaida O; Trihia H; Lekka I
J BUON; 2012; 17(2):277-83. PubMed ID: 22740206
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
